Combination of targeted agents in metastatic renal cell carcinoma

被引：8

作者：

Michaelson, M. Dror ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

来源：

CANCER | 2012年 / 118卷 / 07期

关键词：

PHASE-I; INTERFERON-ALPHA; SUNITINIB; TEMSIROLIMUS; BEVACIZUMAB; EVEROLIMUS; TRIAL;

D O I：

10.1002/cncr.26427

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1744 / 1746

页数：3

共 21 条

[1]

[Anonymous], J CLIN ONCOL

[2] Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status [J].

Bhargava, Pankaj ;

Robinson, Murray O. .

CURRENT ONCOLOGY REPORTS, 2011, 13 (02) :103-111

[3]

Escudier B. J., 2010, J CLIN ONCOL S, V28, pa4516

[4] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[5] Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma [J].

Feldman, Darren R. ;

Baum, Michael S. ;

Ginsberg, Michelle S. ;

Hassoun, Hani ;

Flombaum, Carlos D. ;

Velasco, Susanne ;

Fischer, Patricia ;

Ronnen, Ellen ;

Ishill, Nicole ;

Patil, Sujata ;

Motzer, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1432-1439

[6] Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma [J].

Hainsworth, John D. ;

Spigel, David R. ;

Burris, Howard A., III ;

Waterhouse, David ;

Clark, Bobby L. ;

Whorf, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2131-2136

[7] A Phase 1 Study of Everolimus and Sorafenib for Metastatic Clear Cell Renal Cell Carcinoma [J].

Harzstark, Andrea L. ;

Small, Eric J. ;

Weinberg, Vivian K. ;

Sun, Janine ;

Ryan, Charles J. ;

Lin, Amy M. ;

Fong, Lawrence ;

Brocks, Dion R. ;

Rosenberg, Jonathan E. .

CANCER, 2011, 117 (18) :4194-4200

[8] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Warren, Mark A. ;

Golshayan, Ali Reza ;

Sahi, Chakshu ;

Eigl, Bernhard J. ;

Ruether, J. Dean ;

Cheng, Tina ;

North, Scott ;

Venner, Peter ;

Knox, Jennifer J. ;

Chi, Kim N. ;

Kollmannsberger, Christian ;

McDermott, David F. ;

Oh, William K. ;

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5794-5799

[9] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[10] Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors [J].

Lockhart, A. Craig ;

Rothenberg, Mace L. ;

Dupont, Jakob ;

Cooper, Wendy ;

Chevalier, Paul ;

Sternas, Lars ;

Buzenet, Giliane ;

Koehler, Elizabeth ;

Sosman, Jeffrey A. ;

Schwartz, Lawrence H. ;

Gultekin, David H. ;

Koutcher, Jason A. ;

Donnelly, Edwin F. ;

Andal, Ric ;

Dancy, Isabelle ;

Spriggs, David R. ;

Tew, William P. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :207-214

← 1 2 3 →